Bridgebio Oncology Therapeutics, Inc. (BBOT)
4.71
-0.06
(-1.26%)
USD |
NASDAQ |
Sep 21, 11:10
Bridgebio Oncology Therapeutics Total Liabilities (Quarterly) : 53.59M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.59M |
| March 31, 2026 | 45.37M |
| December 31, 2025 | 37.98M |
| September 30, 2025 | 38.09M |
| June 30, 2025 | 8.149M |
| March 31, 2025 | 7.391M |
| Date | Value |
|---|---|
| December 31, 2024 | 19.59M |
| September 30, 2024 | 5.647M |
| June 30, 2024 | 5.599M |
| March 31, 2024 | 5.543M |
| December 31, 2023 | 0.3965M |
| December 31, 2022 | 0.1665M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.873M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 376.71M |
| Shareholders Equity (Quarterly) | 323.11M |
| Debt to Equity Ratio | 0.0078 |
| Current Ratio | 4.694 |
| Net Debt Paydown Yield | -0.08% |